49 related articles for article (PubMed ID: 37105116)
1. Inhibiting CDK4/6 in pancreatic ductal adenocarcinoma via microRNA-21.
Mortoglou M; Miralles F; Mould RR; Sengupta D; Uysal-Onganer P
Eur J Cell Biol; 2023 Jun; 102(2):151318. PubMed ID: 37105116
[TBL] [Abstract][Full Text] [Related]
2. CDK4/6 inhibition sensitizes MEK inhibition by inhibiting cell cycle and proliferation in pancreatic ductal adenocarcinoma.
Cheng K; Zhou Z; Chen Q; Chen Z; Cai Y; Cai H; Wu S; Gao P; Cai Y; Zhou J; Wang X; Wu Z; Peng B
Sci Rep; 2024 Apr; 14(1):8389. PubMed ID: 38600093
[TBL] [Abstract][Full Text] [Related]
3. Complement factor B regulates cellular senescence and is associated with poor prognosis in pancreatic cancer.
Shimazaki R; Takano S; Satoh M; Takada M; Miyahara Y; Sasaki K; Yoshitomi H; Kagawa S; Furukawa K; Takayashiki T; Kuboki S; Sogawa K; Motohashi S; Nomura F; Miyazaki M; Ohtsuka M
Cell Oncol (Dordr); 2021 Aug; 44(4):937-950. PubMed ID: 34075561
[TBL] [Abstract][Full Text] [Related]
4. Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma.
Afaq F; Agarwal S; Bajpai P; Diffalha SA; Kim HG; Peter S; Khushman M; Chauhan SC; Mukherjee P; Varambally S; Manne U
Neoplasia; 2024 Jan; 47():100951. PubMed ID: 38039923
[TBL] [Abstract][Full Text] [Related]
5. CDK4/6 and IGF1 receptor inhibitors synergize to suppress the growth of p16INK4A-deficient pancreatic cancers.
Heilmann AM; Perera RM; Ecker V; Nicolay BN; Bardeesy N; Benes CH; Dyson NJ
Cancer Res; 2014 Jul; 74(14):3947-58. PubMed ID: 24986516
[TBL] [Abstract][Full Text] [Related]
6. Combination of miR‑143 and miR‑506 reduces lung and pancreatic cancer cell growth through the downregulation of cyclin‑dependent kinases.
Hossian AKMN; Mackenzie GG; Mattheolabakis G
Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33649787
[TBL] [Abstract][Full Text] [Related]
7. Knockdown of TACC3 inhibits tumor cell proliferation and increases chemosensitivity in pancreatic cancer.
Shi S; Guo D; Ye L; Li T; Fei Q; Lin M; Yu X; Jin K; Wu W
Cell Death Dis; 2023 Nov; 14(11):778. PubMed ID: 38012214
[TBL] [Abstract][Full Text] [Related]
8. Concurrent targeting of GSK3 and MEK as a therapeutic strategy to treat pancreatic ductal adenocarcinoma.
Fukuda J; Kosuge S; Satoh Y; Sekiya S; Yamamura R; Ooshio T; Hirata T; Sato R; Hatanaka KC; Mitsuhashi T; Nakamura T; Matsuno Y; Hatanaka Y; Hirano S; Sonoshita M
Cancer Sci; 2024 Apr; 115(4):1333-1345. PubMed ID: 38320747
[TBL] [Abstract][Full Text] [Related]
9. Pancreatic circulating tumor cell profiling identifies LIN28B as a metastasis driver and drug target.
Franses JW; Philipp J; Missios P; Bhan I; Liu A; Yashaswini C; Tai E; Zhu H; Ligorio M; Nicholson B; Tassoni EM; Desai N; Kulkarni AS; Szabolcs A; Hong TS; Liss AS; Fernandez-Del Castillo C; Ryan DP; Maheswaran S; Haber DA; Daley GQ; Ting DT
Nat Commun; 2020 Jul; 11(1):3303. PubMed ID: 32620742
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic priming targets tumor heterogeneity to shift transcriptomic phenotype of pancreatic ductal adenocarcinoma towards a Vitamin D susceptible state.
He B; Stoffel L; He CJ; Cho K; Li AM; Jiang H; Flowers BM; Nguyen KT; Wang KW; Zhao AY; Zhou MN; Ferreira S; Attardi LD; Ye J
Cell Death Dis; 2024 Jan; 15(1):89. PubMed ID: 38272889
[TBL] [Abstract][Full Text] [Related]
11. MYC-mediated resistance to trametinib and HCQ in PDAC is overcome by CDK4/6 and lysosomal inhibition.
Silvis MR; Silva D; Rohweder R; Schuman S; Gudipaty S; Truong A; Yap J; Affolter K; McMahon M; Kinsey C
J Exp Med; 2023 Mar; 220(3):. PubMed ID: 36719686
[TBL] [Abstract][Full Text] [Related]
12. Metabolic Rewiring and Stemness: A Critical Attribute of Pancreatic Cancer Progression.
Ogunleye AO; Nimmakayala RK; Batra SK; Ponnusamy MP
Stem Cells; 2023 May; 41(5):417-430. PubMed ID: 36869789
[TBL] [Abstract][Full Text] [Related]
13. Protein Arginine Methyltransferases in Pancreatic Ductal Adenocarcinoma: New Molecular Targets for Therapy.
Bhandari K; Ding WQ
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612768
[TBL] [Abstract][Full Text] [Related]
14. Development of Gemcitabine-Modified miRNA Mimics as Cancer Therapeutics for Pancreatic Ductal Adenocarcinoma.
Yuen JG; Hwang GR; Fesler A; Intriago E; Pal A; Ojha A; Ju J
bioRxiv; 2023 Aug; ():. PubMed ID: 37645827
[TBL] [Abstract][Full Text] [Related]
15. A Current Synopsis of the Emerging Role of Extracellular Vesicles and Micro-RNAs in Pancreatic Cancer: A Forward-Looking Plan for Diagnosis and Treatment.
Trifylli EM; Kriebardis AG; Koustas E; Papadopoulos N; Fortis SP; Tzounakas VL; Anastasiadi AT; Sarantis P; Vasileiadi S; Tsagarakis A; Aloizos G; Manolakopoulos S; Deutsch M
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542378
[TBL] [Abstract][Full Text] [Related]
16. Genome-wide CRISPR screens identify PKMYT1 as a therapeutic target in pancreatic ductal adenocarcinoma.
Wang S; Xiong Y; Luo Y; Shen Y; Zhang F; Lan H; Pang Y; Wang X; Li X; Zheng X; Lu X; Liu X; Cheng Y; Wu T; Dong Y; Lu Y; Cui J; Jia X; Yang S; Wang L; Wang Y
EMBO Mol Med; 2024 Apr; ():. PubMed ID: 38570712
[TBL] [Abstract][Full Text] [Related]
17. HOTAIR-EZH2 inhibitor AC1Q3QWB upregulates CWF19L1 and enhances cell cycle inhibition of CDK4/6 inhibitor palbociclib in glioma.
Shi J; Lv S; Wu M; Wang X; Deng Y; Li Y; Li K; Zhao H; Zhu X; Ye M
Clin Transl Med; 2020 Jan; 10(1):182-198. PubMed ID: 32508030
[TBL] [Abstract][Full Text] [Related]
18. The expression of genes contributing to pancreatic adenocarcinoma progression is influenced by the respective environment.
Sagini MN; Zepp M; Bergmann F; Bozza M; Harbottle R; Berger MR
Genes Cancer; 2018 Mar; 9(3-4):114-129. PubMed ID: 30108682
[TBL] [Abstract][Full Text] [Related]
19. Correction: PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer.
Ali LR; Garrido-Castro AC; Lenehan PJ; Bollenrucher N; Stump CT; Dougan M; Goel S; Shapiro GI; Tolaney SM; Dougan SK
J Exp Med; 2023 Sep; 220(9):. PubMed ID: 37615687
[No Abstract] [Full Text] [Related]
20. BRCA Mutations and MicroRNA Expression Patterns in the Peripheral Blood of Breast Cancer Patients.
Alavanda C; Dirimtekin E; Mortoglou M; Arslan Ates E; Guney AI; Uysal-Onganer P
ACS Omega; 2024 Apr; 9(15):17217-17228. PubMed ID: 38645356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
